INmune Bio, Inc. (INMB) Bundle
An Overview of INmune Bio, Inc. (INMB)
General Summary of INmune Bio, Inc. (INMB)
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer, neurodegenerative diseases, and immunotherapy. Founded in 2015 and headquartered in San Diego, California.
| Company Metric | Details |
|---|---|
| Ticker Symbol | INMB |
| Founding Year | 2015 |
| Headquarters | San Diego, California |
Key Product Portfolio
- XPro1595 - Neuroinflammation therapeutic
- DNax-NK - Natural killer cell immunotherapy
- INKmune - Cancer immunotherapy platform
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $3.2 million |
| Net Loss | $44.7 million |
| Cash and Investments | $57.4 million |
Industry Leadership
INmune Bio represents an innovative biotechnology company developing advanced immunotherapeutic approaches for complex medical conditions.
Clinical trials ongoing in multiple therapeutic areas demonstrate the company's commitment to breakthrough medical technologies.
Mission Statement of INmune Bio, Inc. (INMB)
Mission Statement of INmune Bio, Inc. (INMB)
INmune Bio, Inc. (INMB) is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer and neurodegenerative diseases.
Core Components of Mission Statement
Therapeutic Focus Areas
| Disease Category | Primary Research Focus | Current Development Stage |
|---|---|---|
| Oncology | Immunotherapy | Clinical Trials |
| Neurodegenerative Diseases | Neuroinflammation Treatment | Preclinical/Clinical Development |
Key Technology Platforms
- XTumorTM Platform for Cancer Immunotherapy
- DN-TNF Technology for Neuroinflammation
- Natural Killer (NK) Cell Targeting
Research and Development Metrics
| Metric | 2024 Value |
|---|---|
| R&D Expenditure | $22.3 million |
| Active Clinical Trials | 4 ongoing trials |
| Patent Portfolio | 12 granted patents |
Strategic Objectives
- Advance precision immunotherapy technologies
- Develop targeted treatments for complex diseases
- Minimize side effects of current therapeutic approaches
Financial Performance Indicators
| Financial Metric | 2024 Value |
|---|---|
| Market Capitalization | $180 million |
| Cash and Equivalents | $45.6 million |
| Research Funding | $15.2 million |
Vision Statement of INmune Bio, Inc. (INMB)
Vision Statement Analysis of INmune Bio, Inc. (INMB) in 2024
Strategic Immunotherapy FocusINmune Bio, Inc. vision centers on developing innovative immunotherapies targeting critical unmet medical needs. As of Q4 2023, the company's market capitalization was approximately $108.4 million.
| Key Vision Components | Strategic Objectives |
|---|---|
| Precision Immunotherapy | Advanced cancer and neuroinflammatory disease treatments |
| Research Investment | $14.3 million allocated for R&D in 2023 |
- XTL therapeutic platform development
- DN-TNF technology advancement
- Targeted immune modulation strategies
Clinical Development Strategy
Current clinical pipeline focuses on:
| Program | Disease Target | Current Phase |
|---|---|---|
| XTL-0019 | Solid Tumors | Phase 1/2 |
| DNT Cell Therapy | Advanced Cancers | Clinical Investigation |
2023 financial metrics relevant to vision implementation:
- Research Expenditure: $14.3 million
- Cash Position: $63.4 million (Q4 2023)
- Operating Expenses: $37.2 million annually
Core Values of INmune Bio, Inc. (INMB)
Core Values of INmune Bio, Inc. (INMB) in 2024
Scientific Innovation and Research Excellence
INmune Bio demonstrates commitment to cutting-edge scientific research in immuno-oncology and neuroinflammation.
| R&D Expenditure (2023) | $22.4 million |
| Active Clinical Trials | 4 ongoing trials |
| Patent Applications | 7 active patents |
Patient-Centric Approach
Focused on developing transformative therapies for complex diseases.
- Targeting neuroinflammatory conditions
- Developing precision immunotherapies
- Prioritizing patient safety in clinical trials
Transparency and Ethical Conduct
Maintaining highest standards of corporate governance and research integrity.
| Independent Board Members | 5 out of 7 board members |
| Compliance Audits (2023) | 2 comprehensive audits |
Collaborative Research Ecosystem
Establishing strategic partnerships with academic and industry research institutions.
- Collaborations with 3 major research universities
- Partnerships with 2 pharmaceutical companies
- Active engagement in scientific conferences
Financial Responsibility and Sustainability
Maintaining robust financial strategy to support long-term research objectives.
| Cash and Cash Equivalents (Q4 2023) | $64.3 million |
| Operating Expenses (2023) | $37.6 million |
| Research Investment Ratio | 62% of total expenses |
INmune Bio, Inc. (INMB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.